Drug Testing Advisory Board (DTAB) Meeting

One Choke Cherry Road, Rockville, MD

Sugarloaf and Seneca Conference Rooms

Exploring the Science and Experience of Testing for Prescription Drugs in the Non-Regulated Workplace

Agenda

August 19, 2008

Open Session (8:30 am - 5:00 pm)

8:30 Call to Order

Donna M. Bush, Ph.D., D-ABFT
Designated Federal Official, DTAB
Drug Testing Team Leader, Division of Workplace Programs (DWP)
Center for Substance Abuse Prevention (CSAP), Substance Abuse
and Mental Health Services (SAMHSA)

8:35 Welcome and Opening Remarks

Robert L. Stephenson II, M.P.H. Chair, DTAB Director, DWP, CSAP, SAMHSA

Moderator: Michael R. Baylor, Ph.D.

Co-Director, Center for Forensic Sciences

RTI International

Morning Session

8:45 Welcome and Opening Remarks

Frances M. Harding Director, CSAP, SAMHSA

Opening Remarks

Bertha K. Madras, Ph.D.
Deputy Director for Demand Reduction
White House Office of National Drug Control Policy (ONDCP)

9:15 Federal Drug Testing Updates

Jim L. Swart, M.S.S.W. Director, Office of Drug and Alcohol Policy and Compliance, Department of Transportation COL Ronald Shippee, Ph.D.
Director, Drug Testing and Program Policy
Department of Defense

9:35 10 CFR Part 26 Fitness for Duty Program

Timothy McCune Program Manager, Fitness for Duty Program, Nuclear Regulatory Commission

9:50 Smart Rx

Mark A. Weber Director, Office of Communications, SAMHSA

10:10 Prescribing Trends for Opioids, Benzodiazepines, Amphetamines and Barbiturates from 1998-2007

Sean J. Belouin, Pharm.D. Lieutenant Commander, United States Public Health Service, DWP, CSAP, SAMHSA

Nicholas Reuter, M.P.H. Senior Public Health Advisor, Division of Pharmacological Therapies, Center for Substance Abuse and Treatment, SAMHSA

10:30 Break

10:45 National Forensic Laboratory Information System (NFLIS)

DeMia Peters, M.S. Chemist, Office of Diversion Control Drug Enforcement Administration

11:05 Prescription Drug Misuse: What can the National Surveys tell us?

Charlene Lewis, Ph.D.

Senior Advisor, Office of Applied Studies, SAMHSA

11:20 National Poison Data System (NPDS): Real-Time Documentation and Surveillance

Alvin C. Bronstein, M.D., FACMT
Associate Professor University of Colorado School of Medicine
Medical Director, Rocky Mountain Poison Center
Director of Surveillance, National Poison Data System
American Association of Poison Control Centers

Paul Starr, Pharm.D, CSPI Specialist, Poison Information, Maryland Poison Center University of Maryland School of Pharmacy

11:40 Drugs and Trauma Center Patients: What Do We Know About Involvement of Prescription Drugs?

Gordon S. Smith, MD, MPH Professor, Epidemiology and Preventative Medicine National Study Center for Trauma and EMS

12:00 DTAB Panel Discussion

12:15 Lunch Break

Afternoon Session

1:45 Prescription Drug Pain Management, Addiction, and Opioid Prescribing Practices

H. Westley Clark, M.D., J.D., M.P.H., FASAM Director, Center for Substance Abuse Treatment, SAMHSA

2:20 Pharmacogenomics of Addiction

Courtney Harper, Ph.D.
Associate Director for Toxicology
Division of Chemistry and Toxicology Devices
Food and Drug Administration

2:45 Break

3:00 Laboratory Testing in Pain Management: Approaches and Issues

Yale H. Caplan, Ph.D., D-ABFT Director, National Scientific Services

3:30 Professional Health Monitoring Programs

Donna R. Smith, Ph.D. Regulatory Affairs and Program Development Officer First Lab

4:00 DTAB Panel Discussion

4:30 Public Comments

5:00 Adjourn

Drug Testing Advisory Board (DTAB) Meeting One Choke Cherry Road, Rockville, MD Sugarloaf and Seneca Conference Rooms

Exploring the Science and Experience of Testing for Prescription Drugs in the Non-Regulated Workplace

Agenda

August 20, 2008

Open Session (8:30 am - 5:00 pm)

8:30 Call to Order

Donna M. Bush, Ph.D., D-ABFT
Designated Federal Official, DTAB
Drug Testing Team Leader, DWP, CSAP, SAMHSA

8:35 Welcome and Opening Remarks

Robert L. Stephenson II, M.P.H. Chair, DTAB Director, DWP, CSAP, SAMHSA

Morning Session

8:40 Immunoassays as an Initial Test in Drug Testing

John M. Mitchell, Ph.D. Co-Director, Center for Forensic Sciences RTI International

9:10 Statistical Trends in Workplace Drug Testing: 2003-2007

R. H. Barry Sample, Ph.D. Director of Science and Technology Quest Diagnostics

9:40 Urine Drug Testing of Pain Patients: Licit and Illicit Drug Patterns and Prevalence

Edward J. Cone, Ph.D. ConeChem Research

10:00 Break

10:15 Laboratory Perspective on Additional Drug Testing and Associated Costs

David Kuntz, Ph.D., D-ABFT Executive Director of Analytical Toxicology

Clinical Reference Laboratory

10:45 Laboratory Perspective on Additional Drug Testing and Associated Costs

Jennifer Collins, Ph.D. Laboratory Director MedTox Laboratories, Inc.

11:15 Drug Testing in Sports

Larry D. Bowers, Ph.D.
Senior Managing Director, Technical and Information
Resources, United States Anti-Doping Agency

11:45 DTAB Panel Discussion

12:00 Lunch Break

Afternoon Session

1:30 Analysis of Urine Drug Testing Results from a Medical Review Officer (MRO) Data Source, 2006-2007

Michael R. Baylor, Ph.D. Co-Director, Center for Forensic Sciences RTI International

A Five Year Analysis of Oral Fluid Drug Testing Results from a Medical Review Officer (MRO) Data Source, 2003-2007

J. Michael Walsh, Ph.D. President, The Walsh Group

MRO Interpretation of Expanded Panel Laboratory Results

James Ferguson, D.O., FASAM Chief Medical Review Officer, Verifications, Inc.

2:30 MROing Prescription Drugs

Robert Swotinsky, M.D., M.P.H., FASAM Chair, Occupational Medicine Department, Fallon Clinic

3:00 Break

3:15 DoD's Experience with Prescription Medications

LTC Timothy P. Lyons, Ph.D. Deputy Director

Forensic Toxicology Division, Armed Forces Institute of Pathology,

Department of Defense

3:45 Review of E. O. 12564 and Reasonableness Donna M. Bush, Ph.D., D-ABFT Designated Federal Official Drug Testing Team Leader, DWP, CSAP, SAMHSA 4:00 DTAB Panel Discussion 4:30 Public Comment 5:00 Adjourn